基于α-病毒复制酶的基因疫苗对人黑色素瘤的免疫作用  

Immunity of genetic vaccine based on alpha virus replicase to human melanoma

作　　者：倪兵[1] 姜曼[1] 黎万玲[1] 毛丽伟[1] 何仰东[1] 肖宇[1] 吴玉章[1] 

机构地区：[1]第三军医大学基础医学部全军免疫学研究所,重庆400038

出　　处：《第三军医大学学报》2005年第14期1432-1435,共4页Journal of Third Military Medical University

基　　金：国家重点基础研究发展规划资目项目("973"项目)~~

摘　　要：目的研究基于α-病毒复制酶的人黑色素瘤基因疫苗免疫学作用。方法建立及鉴定人/鼠嵌合模型(trim-era),将基于α-病毒复制酶的mage-3基因疫苗免疫动物,检测动物体内特异抗体滴度;用标准4h51Cr释放实验检测动物体内特异CTL活性。结果FACS分析显示,trimera小鼠腹腔细胞中人白细胞占总细胞的88·84%,脾脏细胞中人白细胞的比例占57%,同国外文献报道一致。基于α-病毒复制酶的重组基因疫苗mage-3/pSMART2a对trimera小鼠免疫后,小鼠腹腔细胞的CTL在效靶比为100∶1时杀伤率达到70%左右,此时的对照组mage-3/pCI-neo组最大杀伤率为40%左右。ELISA结果显示,重组基因疫苗mage-3/pSMART2a组产生的mage-3抗原特异性抗体效价达到1∶512,mage-3/pCI-neo组为1∶256。结论成功建立了人/鼠嵌合模型,并在动物体内激发出针对人黑色素瘤基因疫苗的初次免疫应答。Objective To study immunological role of human melanoma genetic vaccine based on alpha virus replicase. Methods After human/mouse chimera model was established and identified, the mice were inoculated with mage-3 gene vaccine based on alpha virus replicase. Specific antibody and activity of specific cytotoxic lymphocyte of the inoculated animals were detected by ELISA and 51Cr release assay to monitor the primary immune response of the vaccines. Results FACS assay indicated that human leucocyte held 88.84% in total enterocoelia lymphocyte of trimera mice and 57% in total lymphocyte of spleen. Maximal cytolysis activity of specific CTL form mage-3/pSMART2a immunized mice reached about 70%, meanwhile the activity of CTL from mage-3/pCI-neo group reached 40%. ELISA assay showed that the titre of mage-3 specific antibody reached 1∶512 and 1∶256 in mage-3/pSMART2a and mage-3/pCI-neo immunized mice respectively. Conclusion Human/mouse chimera model has been established successfully and primary immune response against human melanoma gene vaccine has been provoked in trimera model mice.

关 键 词：α-病毒 复制酶 基因疫苗 trimera 人黑色素瘤 

分 类 号：R392.11[医药卫生—免疫学] R394.8[医药卫生—基础医学]